For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
After finishing at $22.98 in the prior trading day, Surgery Partners Inc (NASDAQ: SGRY) closed at $23.56, up 2.52%. In other words, the price has increased by $2.52 from its previous closing price. On the day, 1.75 million shares were traded. SGRY stock price reached its highest trading level at $23.81 during the session, while it also had its lowest trading level at $23.0.
Ratios:
Our goal is to gain a better understanding of SGRY by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 12.08 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 17.23. For the most recent quarter (mrq), Quick Ratio is recorded 1.78 and its Current Ratio is at 1.93. In the meantime, Its Debt-to-Equity ratio is 2.22 whereas as Long-Term Debt/Eq ratio is at 2.13.
On December 16, 2024, BofA Securities started tracking the stock assigning a Buy rating and target price of $30.
On October 14, 2024, UBS started tracking the stock assigning a Buy rating and target price of $38.UBS initiated its Buy rating on October 14, 2024, with a $38 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 11 ’25 when Maryland Patricia Anne sold 20,018 shares for $22.74 per share. The transaction valued at 455,209 led to the insider holds 4,565 shares of the business.
YAWAOG ENTERPRISES CORP bought 20,018 shares of SGRY for $473,226 on Aug 11 ’25. On Aug 08 ’25, another insider, Doherty David T, who serves as the Chief Financial Officer of the company, sold 47,491 shares for $23.39 each. As a result, the insider received 1,110,814 and left with 103,377 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SGRY now has a Market Capitalization of 3020603904 and an Enterprise Value of 8398172672. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.93 while its Price-to-Book (P/B) ratio in mrq is 1.73. Its current Enterprise Value per Revenue stands at 2.594 whereas that against EBITDA is 13.022.
Stock Price History:
The Beta on a monthly basis for SGRY is 1.77, which has changed by -0.21414274 over the last 52 weeks, in comparison to a change of 0.16657472 over the same period for the S&P500. Over the past 52 weeks, SGRY has reached a high of $33.97, while it has fallen to a 52-week low of $18.87. The 50-Day Moving Average of the stock is 5.96%, while the 200-Day Moving Average is calculated to be 1.66%.
Shares Statistics:
The stock has traded on average 1.69M shares per day over the past 3-months and 2103010 shares per day over the last 10 days, according to various share statistics. A total of 128.21M shares are outstanding, with a floating share count of 75.93M. Insiders hold about 40.77% of the company’s shares, while institutions hold 65.56% stake in the company. Shares short for SGRY as of 1753920000 were 12831465 with a Short Ratio of 7.59, compared to 1751241600 on 11426092. Therefore, it implies a Short% of Shares Outstanding of 12831465 and a Short% of Float of 21.219999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current market rating for Surgery Partners Inc (SGRY) reflects the collective analysis of 12.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $0.47, with high estimates of $0.61 and low estimates of $0.32.
Analysts are recommending an EPS of between $1.06 and $0.57 for the fiscal current year, implying an average EPS of $0.85. EPS for the following year is $1.04, with 12.0 analysts recommending between $1.65 and $0.69.
Revenue Estimates
12 analysts predict $824.47M in revenue for the current quarter. It ranges from a high estimate of $839.4M to a low estimate of $803.8M. As of the current estimate, Surgery Partners Inc’s year-ago sales were $770.4MFor the next quarter, 12 analysts are estimating revenue of $931.4M. There is a high estimate of $951.2M for the next quarter, whereas the lowest estimate is $904.35M.
A total of 12 analysts have provided revenue estimates for SGRY’s current fiscal year. The highest revenue estimate was $3.39B, while the lowest revenue estimate was $3.32B, resulting in an average revenue estimate of $3.36B. In the same quarter a year ago, actual revenue was $3.11BBased on 12 analysts’ estimates, the company’s revenue will be $3.69B in the next fiscal year. The high estimate is $3.77B and the low estimate is $3.62B.
